Financial Ratios

PARENTERAL DRUGS (INDIA) LTD.

NSE : PDPLBSE : 524689ISIN CODE : INE904D01019Industry : Pharmaceuticals & DrugsHouse : Private
BSE3.390 (0 %)
PREV CLOSE ( ) 3.39
OPEN PRICE ( ) 3.08
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1250
TODAY'S LOW / HIGH ( )3.08 3.39
52 WK LOW / HIGH ( )3.08 4.14
NSE2.900 (0 %)
PREV CLOSE( ) 2.90
OPEN PRICE ( ) 2.70
BID PRICE (QTY) 2.90 (1373)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1063
TODAY'S LOW / HIGH( ) 2.70 2.90
52 WK LOW / HIGH ( )2.7 3.4
Select year
ParticularsMar2021Mar2020Mar2019Mar2018Mar2017
Operational & Financial Ratios
   Earnings Per Share (Rs)-40.82-38.26-49.61-32.23-38.26
   CEPS(Rs)-35.01-32.44-26.42-26.00-31.86
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)-253.30-212.53-174.17-124.48-92.24
   Tax Rate(%)21.2119.5218.4619.528.85
Margin Ratios
   Core EBITDA Margin(%)-96.75-46.07-49.54-48.35-70.82
   EBIT Margin(%)-238.62-99.70-256.85-100.28-97.29
   Pre Tax Margin(%)-1269.53-444.66-545.94-362.14-237.72
   PAT Margin (%)-1000.30-357.87-445.15-291.44-216.68
   Cash Profit Margin (%)-857.90-303.45-237.12-235.13-180.41
Performance Ratios
   ROA(%)-29.75-26.80-26.26-13.69-14.08
   ROE(%)0.000.000.000.000.00
   ROCE(%)0.00-53.44-44.28-10.50-10.80
   Asset Turnover(x)0.030.070.060.050.06
   Sales/Fixed Asset(x)0.020.040.040.040.07
   Working Capital/Sales(x)-0.01-0.03-0.04-0.07-0.17
Efficiency Ratios
   Fixed Capital/Sales(x)64.6324.6723.6723.8314.91
   Receivable days0.000.000.00319.52493.98
   Inventory Days42.6929.9228.6720.3160.73
   Payable days507.22571.65718.78727.18214.96
Valuation Parameters
   PER(x)0.000.000.000.000.00
   PCE(x)-0.09-0.08-0.33-0.62-0.86
   Price/Book(x)-0.01-0.01-0.05-0.13-0.30
   Yield(%)0.000.000.000.000.00
   EV/Net Sales(x)52.9320.1419.9620.8013.75
   EV/Core EBITDA(x)-55.01-44.48-40.87-47.29-22.41
   EV/EBIT(x)-22.18-20.20-7.77-20.74-14.01
   EV/CE(x)1.611.541.530.991.01
   M Cap / Sales0.780.230.791.451.56
Growth Ratio
   Net Sales Growth(%)-61.83-4.020.78-36.88-64.91
   Core EBITDA Growth(%)18.8711.03-11.9054.7429.60
   EBIT Growth(%)8.6362.76-158.1235.4618.82
   PAT Growth(%)-6.7022.88-53.9215.77-5.16
   EPS Growth(%)-6.7022.88-53.9215.77-5.16
Financial Stability Ratios
   Total Debt/Equity(x)-0.84-1.00-1.23-1.72-2.32
   Current Ratio(x)0.060.070.080.120.18
   Quick Ratio(x)0.060.070.070.120.17
   Interest Cover(x)-0.23-0.29-0.89-0.38-0.69
   Total Debt/Mcap(x)67.1485.1424.3413.397.83

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.